The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab lengthens the time a patient remains free of leukemia symptoms.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)
Timeframe: Mean observation time at time of analysis was approximately 26 months
Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)
Timeframe: Mean observation time at time of analysis was approximately 26 months
Final Analysis: Time to Progression-Free Survival Event
Timeframe: Median observation time was approximately 5 years